131 related articles for article (PubMed ID: 17260365)
1. Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.
de Bièvre MA; Vrij AA; Schoon EJ; Dijkstra G; de Jong AE; Oberndorff-Klein Woolthuis AH; Hemker HC; Stockbrügger RW
Inflamm Bowel Dis; 2007 Jun; 13(6):753-8. PubMed ID: 17260365
[TBL] [Abstract][Full Text] [Related]
2. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
Chande N; McDonald JW; Macdonald JK; Wang JJ
Cochrane Database Syst Rev; 2010 Oct; (10):CD006774. PubMed ID: 20927749
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis.
Bloom S; Kiilerich S; Lassen MR; Forbes A; Leiper K; Langholz E; Irvine EJ; O'Morain C; Lowson D; Orm S
Aliment Pharmacol Ther; 2004 Apr; 19(8):871-8. PubMed ID: 15080848
[TBL] [Abstract][Full Text] [Related]
4. Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.
Vrij AA; Oberndorff-Klein-Woolthuis A; Dijkstra G; de Jong AE; Wagenvoord R; Hemker HC; Stockbrügger RW
J Thromb Thrombolysis; 2007 Oct; 24(2):175-82. PubMed ID: 17308963
[TBL] [Abstract][Full Text] [Related]
5. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials.
Chande N; MacDonald JK; Wang JJ; McDonald JW
Inflamm Bowel Dis; 2011 Sep; 17(9):1979-86. PubMed ID: 21618363
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis.
Zahn A; Hinz U; Karner M; Ehehalt R; Stremmel W
Inflamm Bowel Dis; 2006 Nov; 12(11):1058-67. PubMed ID: 17075347
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
8. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis.
Pena-Rossi C; Schreiber S; Golubovic G; Mertz-Nielsen A; Panes J; Rachmilewitz D; Shieh MJ; Simanenkov VI; Stanton D; Graffner H
Aliment Pharmacol Ther; 2008 Sep; 28(6):758-67. PubMed ID: 19145731
[TBL] [Abstract][Full Text] [Related]
11. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial.
Tamaki H; Nakase H; Inoue S; Kawanami C; Itani T; Ohana M; Kusaka T; Uose S; Hisatsune H; Tojo M; Noda T; Arasawa S; Izuta M; Kubo A; Ogawa C; Matsunaka T; Shibatouge M
Dig Endosc; 2016 Jan; 28(1):67-74. PubMed ID: 26418574
[TBL] [Abstract][Full Text] [Related]
13. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis.
Pastorelli L; Saibeni S; Spina L; Signorelli C; Celasco G; de Franchis R; Vecchi M
Aliment Pharmacol Ther; 2008 Sep; 28(5):581-8. PubMed ID: 18700898
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
Lewis JD; Lichtenstein GR; Deren JJ; Sands BE; Hanauer SB; Katz JA; Lashner B; Present DH; Chuai S; Ellenberg JH; Nessel L; Wu GD;
Gastroenterology; 2008 Mar; 134(3):688-95. PubMed ID: 18325386
[TBL] [Abstract][Full Text] [Related]
16. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
Törkvist L; Thorlacius H; Sjöqvist U; Bohman L; Lapidus A; Flood L; Agren B; Raud J; Löfberg R
Aliment Pharmacol Ther; 1999 Oct; 13(10):1323-8. PubMed ID: 10540047
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
19. Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study.
Kucharzik T; Lemmnitz G; Abels C; Maaser C
Inflamm Bowel Dis; 2017 Feb; 23(2):261-271. PubMed ID: 28092306
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial.
Musch E; Andus T; Kruis W; Raedler A; Spehlmann M; Schreiber S; Krakamp B; Malek M; Malchow H; Zavada F; Engelberg Feurle G
Clin Gastroenterol Hepatol; 2005 Jun; 3(6):581-6. PubMed ID: 15952100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
